[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356809-105":59,"doc-detail-356809-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","selective-nanobody-derived-minibodies-targeting-galectin-1-and-7-reveal-non-redundant-glyco-immune-functions-and-therapeutic-potential-in-triple-negative-breast-cancer","Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer","","Galectins function as glyco-immune checkpoints, yet overlapping expression complicates dissecting their roles and inhibiting them selectively in triple-negative breast cancer. This study contrasts GAL-1 and GAL-7, defines selective nanobody-derived minibodies G1M1 and G7M8, and shows distinct cytokine programs in TNBC cells. In vivo, both minibodies reduce pro-tumor cytokines and enhance antitumor immunity, including improved outcomes alone and with anti-PD-1, supporting therapeutic potential for expanded immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/selective-nanobody-derived-minibodies-targeting-galectin-1-and-7-reveal-non-redundant-glyco-immune-functions-and-therapeutic-potential-in-triple-negative-breast-cancer/356809/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/selective-nanobody-derived-minibodies-targeting-galectin-1-and-7-reveal-non-redundant-glyco-immune-functions-and-therapeutic-potential-in-triple-negative-breast-cancer/356809.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What challenge does the study address about galectins in cancer immunotherapy?","Question",{"text":112,"@type":113},"Galectins act as glyco-immune checkpoints, but their overlapping expression makes it difficult to separate distinct functions and to target them with precise inhibition strategies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are GAL-1 and GAL-7 investigated in triple-negative breast cancer?",{"text":117,"@type":113},"The study compares their distinct molecular and immunological roles in TNBC and develops highly selective nanobody-derived minibodies, G1M1 for GAL-1 and G7M8 for GAL-7, to target each protein specifically.",{"name":119,"@type":110,"acceptedAnswer":120},"What key functional differences are observed when targeting GAL-1 vs GAL-7?",{"text":121,"@type":113},"In TNBC cells, GAL-1 drives a cytokine profile associated with pro-tumor mediators such as G-CSF and VEGF-A, whereas GAL-7 promotes immunomodulatory cytokines, indicating nonredundant functions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356809,1791076556,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Article   \nSelective Nanobody-Derived Minibodies Targeting Galectin‑1 and-7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer  \nRita Nehmé, Marl̀ene Fortier, Philippine Granger Joly de Boissel, France Caza, Fanny Fronton, Léa Bourguignon, Tania Charpentier, Camille Fuselier, Sophia Ferchiou, Noémie D’Auteuil, Louis Gaboury, Alain Lamarre, David Chatenet, and Yves St-Pierre*  \n Cite This: J. Med. Chem. 2026, 69, 10949−10963  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Galectins (GALs) act as glyco-immune checkpoints that modulate tumor immunity, but their overlapping expression complicates functional dissection and targeted inhibition. Here, we explore the distinct molecular and immunological roles of GAL-1 and GAL-7, two GAL sover expressed in triple-negative breast cancer (TNBC), and describe the development of highly selective nanobody-derived minibodies (G1M1 and G7M8) that specifically target each protein. In TNBC cells, GAL-1 and GAL-7 induced different cytokine profiles: GAL-1 increased pro-tumor mediators such as G-CSF and VEGF-A, while GAL-7 promoted immunomodulatory cytokines, highlighting their nonredundant functions. In vivo, both G1M1 and G7M8 reduced pro-tumor cytokines and boosted antitumor immunity, either alone or combined with anti  \nPD-1 therapy. Notably, G1M1 alone achieved results comparable to anti-PD-1 therapy in limiting lung metastases, increasing CD4+ T-cell infiltration, and decreasing PD-1+ Tregs. These findings demonstrate that selective GAL blockade with engineered minibodies is a promising strategy to expand immunotherapy options in TNBC.  \n■ INTRODUCTION  \nImmunotherapy has marked a paradigm shift in the field of oncology by offering new treatment options that can lead to durable responses and improved survival rates across various types of cancer. It has particularly opened new avenues for treating aggressive cancers with limited therapeutic options, such as triple-negative breast cancer (TNBC). As more specific molecular drivers are identified, novel therapeutic strategies have emerged, particularly in the field of immunotherapy. The success of immunotherapy currently relies on inhibiting immune checkpoints, which target the immunosuppressive mechanisms driven by cancer cells, thereby allowing the patient’s immune system to mount an effective antitumor response. Today, immunotherapy using immune checkpoint inhibitors, such as anti-PD-1, is part of the first-line treatment for patients with aggressive cancers, including TNBC. 1−5 Unfortunately, the success rate of immunotherapy varies significantly among patients. Not all patients respond to immunotherapy, and predicting which patients will respond remains a major challenge.6,7 Moreover, many patients who initially respond to immunotherapy may later develop resistance to it.  \nGalectins (GALs) are a family of evolutionarily conserved animal lectins that are broadly distributed across species, ranging  \nfrom invertebrates to vertebrates. They were first identified in the electric eel (Electrophorus electricus) as low-molecularweight, β-galactoside-binding soluble proteins. Since their initial discovery, 15 GALs have been sequentially numbered based on their structural characteristics and the number of carbohydrate recognition domains (CRDs) . While GALs have various homeostatic roles within cells, they are predominantly recognized for their functions outside the cell. In pathological conditions, GALs are secreted into the extracellular environment through nonclassical pathways. Once outside the cell, they bind multivalently to repeating units of high-density N-and Oglycans on membrane receptors via their glycan-binding sites, located within their CRDs. This interaction is believ","cbCaipFm1siT5IfJ","https://ap.wps.com/l/cbCaipFm1siT5IfJ","pdf",8185280,15,"English","# Abstract\n# Introduction\n## Immunotherapy and immune checkpoint inhibitors\n## Galectins: structure, secretion, and extracellular glycan binding\n## Roles of galectins in cancer and immune modulation","[{\"question\":\"What challenge does the study address about galectins in cancer immunotherapy?\",\"answer\":\"Galectins act as glyco-immune checkpoints, but their overlapping expression makes it difficult to separate distinct functions and to target them with precise inhibition strategies.\"},{\"question\":\"How are GAL-1 and GAL-7 investigated in triple-negative breast cancer?\",\"answer\":\"The study compares their distinct molecular and immunological roles in TNBC and develops highly selective nanobody-derived minibodies, G1M1 for GAL-1 and G7M8 for GAL-7, to target each protein specifically.\"},{\"question\":\"What key functional differences are observed when targeting GAL-1 vs GAL-7?\",\"answer\":\"In TNBC cells, GAL-1 drives a cytokine profile associated with pro-tumor mediators such as G-CSF and VEGF-A, whereas GAL-7 promotes immunomodulatory cytokines, indicating nonredundant functions.\"}]","Selective Nanobody-Derived Minibodies Targeting Galectin-1 and -7 Reveal Non-Redundant Glyco-Immune Functions and Therapeutic Potential in Triple-Negative Breast Cancer | PDF",1790127425,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0caebf825fa3668e4dde2a70ac84970c.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fdb7d30035a8bea0f78c12cd9d47feb.webp",982,1295,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3359052539e835a77adb71600c6596d.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cf86af4de4c502bf90eecb691c4eed8.webp",980,1292]